GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
Indivior
INDV
$3.12B
| $33.3K | ﹤0.01% |
3,490
+628
| +22% | +$5.99K |
|
|
CNTA
452
Centessa Pharmaceuticals
CNTA
$2.11B
| $32.8K | ﹤0.01% |
2,283
+411
| +22% | +$5.91K |
|
453
Wave Life Sciences
WVE
$1.32B
| $31.6K | ﹤0.01% |
3,905
+703
| +22% | +$5.68K |
|
454
ARS Pharmaceuticals
SPRY
$995M
| $31.3K | ﹤0.01% |
2,488
+447
| +22% | +$5.62K |
|
|
GTY
455
Getty Realty Corp
GTY
$1.63B
| $30.9K | ﹤0.01% |
990
+55
| +6% | +$1.72K |
|
|
LTC
456
LTC Properties
LTC
$1.69B
| $30.4K | ﹤0.01% |
857
+67
| +8% | +$2.38K |
|
457
DiamondRock Hospitality
DRH
$1.76B
| $30.4K | ﹤0.01% |
3,932
+166
| +4% | +$1.28K |
|
458
Immunocore
IMCR
$1.87B
| $30.1K | ﹤0.01% |
1,014
+183
| +22% | +$5.43K |
|
459
Global Net Lease
GNL
$1.77B
| $29.9K | ﹤0.01% |
3,713
+153
| +4% | +$1.23K |
|
460
Ardelyx
ARDX
$1.57B
| $29.8K | ﹤0.01% |
6,064
+1,091
| +22% | +$5.36K |
|
461
Ocular Therapeutix
OCUL
$2.37B
| $29.5K | ﹤0.01% |
4,026
+725
| +22% | +$5.31K |
|
462
Aurinia Pharmaceuticals
AUPH
$1.63B
| $29.5K | ﹤0.01% |
3,666
+660
| +22% | +$5.31K |
|
463
Pacira BioSciences
PCRX
$1.19B
| $29.4K | ﹤0.01% |
1,182
+212
| +22% | +$5.27K |
|
464
Innovative Industrial Properties
IIPR
$1.61B
| $29K | ﹤0.01% |
537
+22
| +4% | +$1.19K |
|
465
Innoviva
INVA
$1.29B
| $29K | ﹤0.01% |
1,602
+288
| +22% | +$5.22K |
|
|
ELME
466
Elme Communities
ELME
$1.52B
| $29K | ﹤0.01% |
1,667
+80
| +5% | +$1.39K |
|
467
Adaptive Biotechnologies
ADPT
$1.96B
| $28.1K | ﹤0.01% |
3,779
+680
| +22% | +$5.05K |
|
|
SILA
468
Sila Realty Trust, Inc.
SILA
$1.4B
| $27.8K | ﹤0.01% |
+1,042
| New | +$27.8K |
|
469
Unity
U
$18.5B
| $27.5K | ﹤0.01% |
+1,403
| New | +$27.5K |
|
470
Dyne Therapeutics
DYN
$2.02B
| $27.2K | ﹤0.01% |
2,605
+468
| +22% | +$4.9K |
|
471
Syndax Pharmaceuticals
SNDX
$1.47B
| $26.9K | ﹤0.01% |
2,186
+394
| +22% | +$4.84K |
|
|
VRE
472
Veris Residential
VRE
$1.52B
| $26.8K | ﹤0.01% |
1,584
+77
| +5% | +$1.3K |
|
|
UMH
473
UMH Properties
UMH
$1.29B
| $26.6K | ﹤0.01% |
1,420
+64
| +5% | +$1.2K |
|
474
Structure Therapeutics
GPCR
$1.27B
| $26.4K | ﹤0.01% |
1,525
+274
| +22% | +$4.74K |
|
475
Novavax
NVAX
$1.28B
| $26.3K | ﹤0.01% |
4,101
+738
| +22% | +$4.73K |
|